Neuromelanin magnetic resonance imaging (NM-MRI) appears to provide a better marker for discriminating advanced Parkinson’s disease (PD) than 123I-N-v-fluoropropyl-2b-carbomethoxy3b-(4-iodophenyl)nortropane labeled dopamine transporter by single photon emission computed tomography (DaT-SPECT).
Why this matters
The occurrence of motor fluctuations (MF) in PD is associated with disease progression and with worsening quality of life; therefore, monitoring the progression of nigrostriatal neuronal degeneration is useful in the management of PD.
Both NM-MRI and DaT-SPECT might be useful for monitoring and evaluating dopaminergic neuronal degeneration.
Möchten Sie mehr lesen?
Loggen Sie sich ein oder registrieren Sie sich, um Zugang zu allen Inhalten von Neurodiem zu erhalten.
Sie haben bereits einen Account? Einloggen
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.